Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells $42,161.10 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRKGet Free Report) General Counsel Junlin Ho sold 4,695 shares of Scholar Rock stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $8.98, for a total value of $42,161.10. Following the sale, the general counsel now owns 204,076 shares in the company, valued at approximately $1,832,602.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $8.30 on Friday. The company has a current ratio of 6.58, a quick ratio of 6.58 and a debt-to-equity ratio of 0.24. Scholar Rock Holding Co. has a 1-year low of $5.93 and a 1-year high of $21.17. The firm’s fifty day moving average price is $12.12 and its 200 day moving average price is $14.81.

Scholar Rock (NASDAQ:SRRKGet Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter last year, the firm earned ($0.46) EPS. Sell-side analysts anticipate that Scholar Rock Holding Co. will post -2.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank grew its stake in shares of Scholar Rock by 15.5% during the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock worth $92,000 after purchasing an additional 652 shares during the period. American International Group Inc. boosted its holdings in Scholar Rock by 3.0% during the first quarter. American International Group Inc. now owns 28,407 shares of the company’s stock worth $505,000 after buying an additional 834 shares in the last quarter. Jennison Associates LLC grew its position in Scholar Rock by 1.0% during the first quarter. Jennison Associates LLC now owns 138,458 shares of the company’s stock worth $2,459,000 after buying an additional 1,409 shares during the period. ProShare Advisors LLC grew its position in Scholar Rock by 11.7% during the first quarter. ProShare Advisors LLC now owns 15,412 shares of the company’s stock worth $274,000 after buying an additional 1,620 shares during the period. Finally, Alps Advisors Inc. increased its holdings in Scholar Rock by 4.1% in the third quarter. Alps Advisors Inc. now owns 41,535 shares of the company’s stock valued at $295,000 after buying an additional 1,628 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Scholar Rock in a research report on Tuesday, June 4th. Raymond James started coverage on shares of Scholar Rock in a research report on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Scholar Rock in a research report on Tuesday, May 7th. BMO Capital Markets increased their price target on shares of Scholar Rock from $29.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, June 13th. Finally, Truist Financial restated a “buy” rating and issued a $20.00 price objective on shares of Scholar Rock in a research note on Wednesday, April 3rd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Scholar Rock has an average rating of “Buy” and an average target price of $26.00.

Check Out Our Latest Research Report on Scholar Rock

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Featured Articles

Insider Buying and Selling by Quarter for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.